These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 29579168)

  • 1. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation.
    Kirchhof P; Haeusler KG; Blank B; De Bono J; Callans D; Elvan A; Fetsch T; Van Gelder IC; Gentlesk P; Grimaldi M; Hansen J; Hindricks G; Al-Khalidi HR; Massaro T; Mont L; Nielsen JC; Nölker G; Piccini JP; De Potter T; Scherr D; Schotten U; Themistoclakis S; Todd D; Vijgen J; Di Biase L
    Eur Heart J; 2018 Aug; 39(32):2942-2955. PubMed ID: 29579168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
    Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
    Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
    Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
    J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.
    Ezekowitz MD; Pollack CV; Halperin JL; England RD; VanPelt Nguyen S; Spahr J; Sudworth M; Cater NB; Breazna A; Oldgren J; Kirchhof P
    Eur Heart J; 2018 Aug; 39(32):2959-2971. PubMed ID: 29659797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
    Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial.
    Haeusler KG; Eichner FA; Heuschmann PU; Fiebach JB; Engelhorn T; Blank B; Callans D; Elvan A; Grimaldi M; Hansen J; Hindricks G; Al-Khalidi HR; Mont L; Nielsen JC; Piccini JP; Schotten U; Themistoclakis S; Vijgen J; Di Biase L; Kirchhof P
    Circulation; 2022 Mar; 145(12):906-915. PubMed ID: 35135308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation.
    Mavrakanas TA; Garlo K; Charytan DM
    Clin J Am Soc Nephrol; 2020 Aug; 15(8):1146-1154. PubMed ID: 32444398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study.
    Rago A; Papa AA; Cassese A; Arena G; Magliocca MCG; D'Onofrio A; Golino P; Nigro G; Russo V
    Am J Cardiovasc Drugs; 2019 Aug; 19(4):421-427. PubMed ID: 30838557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apixaban versus warfarin in patients with atrial fibrillation.
    Granger CB; Alexander JH; McMurray JJ; Lopes RD; Hylek EM; Hanna M; Al-Khalidi HR; Ansell J; Atar D; Avezum A; Bahit MC; Diaz R; Easton JD; Ezekowitz JA; Flaker G; Garcia D; Geraldes M; Gersh BJ; Golitsyn S; Goto S; Hermosillo AG; Hohnloser SH; Horowitz J; Mohan P; Jansky P; Lewis BS; Lopez-Sendon JL; Pais P; Parkhomenko A; Verheugt FW; Zhu J; Wallentin L;
    N Engl J Med; 2011 Sep; 365(11):981-92. PubMed ID: 21870978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation.
    Ukaigwe A; Shrestha P; Karmacharya P; Hussain SK; Samii S; Gonzalez MD; Wolbrette D; Naccarrelli GV
    J Interv Card Electrophysiol; 2017 Mar; 48(2):223-233. PubMed ID: 27771820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study.
    Reinecke H; Engelbertz C; Bauersachs R; Breithardt G; Echterhoff HH; Gerß J; Haeusler KG; Hewing B; Hoyer J; Juergensmeyer S; Klingenheben T; Knapp G; Christian Rump L; Schmidt-Guertler H; Wanner C; Kirchhof P; Goerlich D
    Circulation; 2023 Jan; 147(4):296-309. PubMed ID: 36335915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial.
    Reynolds MR; Allison JS; Natale A; Weisberg IL; Ellenbogen KA; Richards M; Hsieh WH; Sutherland J; Cannon CP
    JACC Clin Electrophysiol; 2018 May; 4(5):580-588. PubMed ID: 29798783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
    Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
    Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial.
    Coppens M; Synhorst D; Eikelboom JW; Yusuf S; Shestakovska O; Connolly SJ
    Eur Heart J; 2014 Jul; 35(28):1856-63. PubMed ID: 24569032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.
    Staerk L; Fosbøl EL; Lip GYH; Lamberts M; Bonde AN; Torp-Pedersen C; Ozenne B; Gerds TA; Gislason GH; Olesen JB
    Eur Heart J; 2017 Mar; 38(12):907-915. PubMed ID: 27742807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apixaban in patients with atrial fibrillation.
    Connolly SJ; Eikelboom J; Joyner C; Diener HC; Hart R; Golitsyn S; Flaker G; Avezum A; Hohnloser SH; Diaz R; Talajic M; Zhu J; Pais P; Budaj A; Parkhomenko A; Jansky P; Commerford P; Tan RS; Sim KH; Lewis BS; Van Mieghem W; Lip GY; Kim JH; Lanas-Zanetti F; Gonzalez-Hermosillo A; Dans AL; Munawar M; O'Donnell M; Lawrence J; Lewis G; Afzal R; Yusuf S;
    N Engl J Med; 2011 Mar; 364(9):806-17. PubMed ID: 21309657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Granger CB; Lopes RD; Hanna M; Ansell J; Hylek EM; Alexander JH; Thomas L; Wang J; Bahit MC; Verheugt F; Lawrence J; Xavier D; Wallentin L
    Am Heart J; 2015 Jan; 169(1):25-30. PubMed ID: 25497244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement.
    Seeger J; Gonska B; Rodewald C; Rottbauer W; Wöhrle J
    JACC Cardiovasc Interv; 2017 Jan; 10(1):66-74. PubMed ID: 27916486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.